New Results from 12M Analysis of ILLUMINATE-B Phase 3 Study of OXLUMO® (lumasiran) Presented at PAS 2022

25 Apr, 2022 New Results from 12M Analysis of ILLUMINATE-B Phase 3 Study of OXLUMO® (lumasiran) Presented at PAS 2022

New results from the 12-month analysis of the ongoing ILLUMINATE-B Phase 3 open-label pediatric study of OXLUMO^® (lumasiran) in patients less than six years of age with primary hyperoxaluria type 1 (PH1) were presented at the Pediatric Academic Societies (PAS) 2022 Meeting (April 21-25, 2022).

Michael, et al. “Efficacy and Safety of Lumasiran for Infants and Young Children With Primary Hyperoxaluria Type 1: 12-Month Analysis of the Phase 3 ILLUMINATE-B Trial”